SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
2.43%18.152.0%$258.39m
SHPGShire PLC Sponsored ADR
-1.90%175.590.4%$221.25m
JAZZJazz Pharmaceuticals Plc
-0.60%142.802.2%$105.01m
PRGOPerrigo Co. Plc
-0.38%63.276.8%$104.98m
ENDPEndo International Plc
-0.31%12.698.9%$64.86m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.50%132.306.3%$64.59m
MNKMallinckrodt Plc
-1.85%30.8521.1%$58.56m
SAGESAGE Therapeutics, Inc.
2.08%114.219.6%$57.88m
HZNPHorizon Pharma plc
2.87%21.867.4%$53.25m
ICPTIntercept Pharmaceuticals, Inc.
1.80%102.7018.7%$51.93m
UTHRUnited Therapeutics Corporation
4.45%121.4914.4%$49.60m
CTLTCatalent Inc
0.87%39.392.4%$40.94m
PTLAPortola Pharmaceuticals, Inc.
-0.99%20.007.7%$34.00m
ICLRICON Plc
-1.58%132.874.1%$33.59m
AERIAerie Pharmaceuticals, Inc.
0.33%42.876.9%$29.36m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.